Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:24 PM
Ignite Modification Date:
2025-12-24 @ 9:24 PM
NCT ID:
NCT01255332
Eligibility Criteria:
Inclusion Criteria:
* 20\~55 years old
* Persistent or chronic ITP patients, defined by international working group ( persistent: between 3 to 12 months from diagnosis, chronic: lasting for more than 12 months)
* 30X109/L ≤ platelet count ≤ 70X109/L
* C13-urea breath test: positive
* no previous ITP treatment
* no previous H. pylori eradication treatment
* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital
Exclusion Criteria:
* Patients who have any cause of thrombocytopenia such as HIV, HCV infection, lymphoproliferative disease, liver disease, definite SLE, drug, MDS, leukemia
* Uncontrolled hypothyroidism or hyperthyroidism
* Acute active bleeding or infection
* Who taking anti-coagulant or aspirin
* Patients with penicillin allergy
* Patients with side effects of macrolide.
* Patients who taking Mizolastine, Terfenadine, Cisapride, Pimozide, Astemizole, Ergot alkaloid and its derivatives (Ergotamine, Dihydroergotamine), Bepridil, or Atazanavir
* Patients who have known allergy or severe side effect on study drugs
* Pregnant or lactating women
* Clinically relevant hepatic or renal disease (Creatinine clearance ≤ 30mL/min)
* patients who cannot understand informed consent or express his/her condition
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
55 Years
Study:
NCT01255332
Study Brief:
Protocol Section:
NCT01255332